Galderma Research & Development, S.N.C.
Records under this name other than the patents Galderma Research & Development, S.N.C. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Galderma Research & Development, S.N.C.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,784,905 | Oil-Extracted Product of Indigo Naturalis, and Preparation Process and Uses Thereof Formerly held Lapsed on the fee record Ended Jul 22, 2026 · High confidence | Lapsed on the fee record | Ended Jul 22, 2026 | High confidence |
| US 7,439,396 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors Term ended Term ended May 23, 2026 · From the USPTO record | Term ended | Term ended May 23, 2026 | From the USPTO record |
| US 7,820,186 | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Term ended Term ended Nov 23, 2025 · From the USPTO record | Term ended | Term ended Nov 23, 2025 | From the USPTO record |
| US 7,579,377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Term ended Term ended Feb 23, 2025 · From the USPTO record | Term ended | Term ended Feb 23, 2025 | From the USPTO record |
| US 7,348,449 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof Term ended Term ended Nov 17, 2024 · From the USPTO record | Term ended | Term ended Nov 17, 2024 | From the USPTO record |
| US 7,468,457 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof Term ended Term ended Sep 5, 2024 · From the USPTO record | Term ended | Term ended Sep 5, 2024 | From the USPTO record |
| US 7,964,202 | Method for treatment of common acne Term ended Term ended Sep 1, 2024 · From the USPTO record | Term ended | Term ended Sep 1, 2024 | From the USPTO record |
| US 7,326,803 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof Term ended Term ended Mar 25, 2024 · From the USPTO record | Term ended | Term ended Mar 25, 2024 | From the USPTO record |
| US 7,838,558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Lapsed on the fee record Ended Nov 23, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 23, 2022 | From the USPTO record |
| US 6,403,656 | Use of ppar-&ggr; activators in dermatology Term ended Term ended Sep 7, 2020 · From the USPTO record | Term ended | Term ended Sep 7, 2020 | From the USPTO record |